Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMDW) Invested Capital (2018 - 2025)

Historic Invested Capital for Revolution Medicines (RVMDW) over the last 8 years, with Q3 2025 value amounting to $1.6 billion.

  • Revolution Medicines' Invested Capital rose 195.36% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 195.36%. This contributed to the annual value of $2.3 billion for FY2024, which is 2403.96% up from last year.
  • As of Q3 2025, Revolution Medicines' Invested Capital stood at $1.6 billion, which was up 195.36% from $1.9 billion recorded in Q2 2025.
  • Revolution Medicines' Invested Capital's 5-year high stood at $2.3 billion during Q4 2024, with a 5-year trough of $498.8 million in Q2 2022.
  • Its 5-year average for Invested Capital is $1.2 billion, with a median of $930.8 million in 2023.
  • As far as peak fluctuations go, Revolution Medicines' Invested Capital plummeted by 2717.71% in 2022, and later skyrocketed by 16652.45% in 2023.
  • Revolution Medicines' Invested Capital (Quarter) stood at $602.6 million in 2021, then grew by 13.71% to $685.2 million in 2022, then soared by 166.52% to $1.8 billion in 2023, then increased by 24.04% to $2.3 billion in 2024, then decreased by 29.5% to $1.6 billion in 2025.
  • Its Invested Capital stands at $1.6 billion for Q3 2025, versus $1.9 billion for Q2 2025 and $2.1 billion for Q1 2025.